Last reviewed · How we verify

pentothal sodium

Ajou University School of Medicine · FDA-approved active Small molecule

Pentothal sodium is a barbiturate that enhances inhibitory neurotransmission by potentiating GABA receptors in the central nervous system, leading to sedation, anesthesia, and anticonvulsant effects.

Pentothal sodium is a barbiturate that enhances inhibitory neurotransmission by potentiating GABA receptors in the central nervous system, leading to sedation, anesthesia, and anticonvulsant effects. Used for Induction and maintenance of general anesthesia, Seizure management and status epilepticus, Sedation for diagnostic and therapeutic procedures.

At a glance

Generic namepentothal sodium
SponsorAjou University School of Medicine
Drug classBarbiturate
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia, Neurology
PhaseFDA-approved

Mechanism of action

Pentothal sodium (thiopental) binds to and allosterically modulates GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization. This results in depression of the central nervous system with dose-dependent effects ranging from sedation to general anesthesia. The drug also has anticonvulsant properties due to its ability to raise seizure threshold.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: